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ABSTRACT
Metastases from melanoma, lung and breast cancer are among the most 
common causes of intracranial malignancy. Standard of care for brain metastases 
include a combination of surgical resection, stereotactic radiosurgery, and whole-
brain radiation. However, evidence continues to accumulate regarding the efficacy 
of molecularly-targeted systemic treatments and immunotherapy. For non-small 
cell lung cancer (NSCLC), numerous clinical trials have demonstrated intracranial 
activity for inhibitors of EGFR and ALK. Patients with melanoma brain metastases may 
benefit from systemic therapy using BRAF-inhibitors with and without trametinib. 
Several targeted options are available for breast cancer brain metastases that 
overexpress HER2, although agents with intracranial activity are still needed for 
other molecular subtypes. Immune checkpoint inhibitors including anti-CTLA-4 
and anti-PD-1/PD-L1 antibodies are yielding impressive responses in intracranial 
manifestations of metastatic melanoma and NSCLC. Given the promising early results 
with these emerging therapies, management of eligible patients will require increased 
multidisciplinary discussion incorporating novel systemic treatment approaches prior 
or in addition to local therapy.
INTRODUCTION
Metastases from systemic cancers are the most 
common type of intracranial malignancy, and the most 
common cancers that lead to brain metastases (BM) are 
lung (16.3% 5-year cumulative incidence), renal (9.8%), 
melanoma (7.4%), and breast (5.0%) [1]. The incidence 
of BM is likely increasing because patients are living 
longer due to more effective systemic therapies, as well as 
increasing use of screening neuroimaging. Traditionally, 
standard therapy for BM has focused on local treatment 
including craniotomy for resection and/or stereotactic 
radiosurgery (SRS), with whole-brain radiation therapy 
(WBRT) reserved for more disseminated intracranial 
disease [2]. A recent set of guidelines produced by the 
Congress of Neurological Surgeons (CNS) and the 
American Association of Neurological Surgeons/CNS 
Section on Tumors provides updated recommendations 
regarding the roles of surgery, SRS, and WBRT but 
concluded that there is insufficient evidence to make 
recommendations regarding molecularly targeted agents 
[3, 4].
Although attractive in many cases, the utility of 
conventional systemic therapy in the treatment of BM 
has historically been limited due to poor penetration 
across the blood-brain (BBB) and blood-tumor barrier 
[5]. Traditional clinical trials for systemic therapies have 
excluded patients with symptomatic or uncontrolled BM 
due to these challenges with central nervous system (CNS) 
penetration [1]. More recently, targeted systemic therapies 
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have demonstrated improved extracranial disease control 
and survival in molecularly defined subpopulations, 
and the ability of these medications to complement or 
even replace local treatment of BM is under intense 
investigation [6]. In fact, a series of recent studies have 
importantly suggested that many targeted agents are 
able to achieve therapeutic concentrations in the brain, 
including EGFR- and ALK- inhibitors for non-small cell 
lung cancer, BRAF- and MEK- inhibitors for melanoma, 
and HER2-directed therapies for breast cancer. In addition, 
systemically delivered immune therapies such as checkpoint 
blockade have also demonstrated efficacy in the CNS [7]. 
Furthermore, while earlier trials were difficult to interpret 
due to variations in response and progression criteria, the 
Response Assessment in Neuro-Oncology Brain Metastases 
(RANO-BM) provided standardization in study assessments 
[8]. This review summarizes emerging evidence for targeted 
systemic therapies for the most common sources of BM, 
which are illustrated in Figure 1.
LUNG CANCER BRAIN METASTASES
Lung cancer is the leading cause of cancer 
death overall, and 13-44% of patients with lung cancer 
ultimately develop BM [9–11]. Although BM are more 
common in small cell lung cancer, most studies have 
focused on the targeted treatment of metastases from 
non-small cell lung cancer (NSCLC) because the latter 
represents a greater proportion (80-85%) of total lung 
cancer cases [9]. NSCLC comprises a heterogeneous 
Figure 1: Schematic diagrams illustrating mechanisms of action for (A) EGFR- and ALK- inhibitors for non-small cell lung cancer, 
(B) BRAF- and MEK- inhibitors for metastatic melanoma, (C) HER2-targeted therapies for breast cancer, and (D) immune checkpoint 
inhibitors. For additional information regarding PD-L1 inhibitors please see article by O’Kane and Leighl [83]. Abbreviations: HER: 
human epidermal growth factor receptor; EGFR: epidermal growth factor receptor; EML4: echinoderm microtubule-associated protein-
like 4; ALK: anaplastic lymphoma kinase; T-DM1: trastuzumab emtansine; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; CD80: 
cluster of differentiation 80; TCR: T-cell receptor; MHC: major histocompatibility complex; PD-1: programmed cell death protein 1; PD-
L1: programmed death-ligand 1.
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group of cancers including squamous cell carcinoma, large 
cell carcinoma, and adenocarcinoma. Several molecular 
driver mutations have been identified within NSCLC 
including mutation of epidermal growth factor receptor 
(EGFR), as well as fusion of anaplastic lymphoma kinase 
(ALK) and echinoderm microtubule-associated protein-
like 4 (EML4) genes [1]. Targeted therapies for NSCLC 
BM have focused on inhibitors of these subclasses of 
tumors (Table 1).
EGFR inhibitors
Mutation of EGFR increases its kinase activity 
thereby promoting tumor cell survival in 10-35% of 
NSCLC [12]. First generation EGFR inhibitors bind 
reversibly to the tyrosine kinase of EGFR, whereas 
second-generation agents bind irreversibly and are 
therefore more potent. Third generation EGFR inhibitors 
have less adverse effects and are active against tumors 
with acquired EGFRT790M mutations [8]. The two first-
generation EGFR inhibitors, erlotinib and gefitinib, have 
shown potent activity within the CNS. However, most 
prospective studies evaluating the efficacy of erlotinib or 
gefitinib for NSCLC BM have used them as second-line 
agents in patients who had been previously treated with 
radiotherapy or chemotherapy [13, 14].
Two published phase II trials have evaluated first-
generation EGFR inhibitors (gefitinib or erlotinib) as 
first-line therapy in patients with EGFR-mutant NSCLC 
with BM [15, 16]. None of the patients in these trials 
had received prior treatment with chemotherapy or 
radiotherapy. Both studies showed favorable response of 
BM to either gefitinib or erlotinib with progression free 
survival (PFS) between 7.1 and 14.5 months and overall 
survival (OS) between 18.8 and 21.9 months. Additional 
studies have evaluated the efficacy of radiotherapy 
combined with EGFR inhibitors in radiotherapy-naïve 
patients with EGFR-mutated NSCLC BM [17–19]. One 
clinical trial using erlotinib concurrently with WBRT 
showed improved PFS (12.3 versus 5.2 months) and OS 
(19.1 versus 9.3 months) in patients with EGFR mutations 
compared to those without [20]. Intracranial response 
rate within the study cohort was 86%, including 31% 
who experienced complete response. Overall, the first-
generation EGFR inhibitors, gefitinib and erlotinib, appear 
to be effective in controlling BM both with and without 
concurrent radiation in patients with EGFR-mutant 
NSCLC.
At present, data are sparse regarding the second 
and third-generation EGFR inhibitors, afatinib and 
osimertinib, respectively, in treatment of NSCLC BM. 
One prospective study assessed the efficacy of afatinib in 
100 patients with NSCLC BM [21]. These patients had 
all failed at least one prior platinum-based chemotherapy 
as well as a first-generation EGFR inhibitor. PFS in 
patients treated with afatinib was 3.6 months, and 
cerebral response rate was 35%. Further clinical trials 
on the efficacy of afatinib for the treatment of NSCLC 
BM are underway (NCT02768337). The third-generation 
EGFR inhibitor, osimertinib, has been approved for 
Table 1: Selected clinical studies of targeted treatments for non-small cell lung cancer brain metastases
Authors & Year Regimen Target (gen.) N cRR (%) PFS (mo) OS (mo)
Kim et al., 2009 Gefitinib or erlotinib EGFR (I) 23 73.9 7.1 18.8
Iuchi et al., 2013 Gefitinib EGFR (I) 41 87.8 14.5 21.9
Welsh et al., 2013 Erlotinib + WBRT EGFR (I) 40 86 8.0 11.8
Hoffknecht et al., 2015 Afatinib EGFR (II) 100 35 3.6 9.8
Kim et al., 2016 (ASCEND-1) Ceritinib ALK (II) 94 68 -- --
Crino et al., 2016 (ASCEND-2) Ceritinib ALK (II) 100 45 5.4 --
Soria et al., 2017 (ASCEND-4) Ceritinib ALK (II) 121 46.3 10.7 --
Shaw et al., 2017 (ASCEND-5) Ceritinib ALK (II) 66 35 4.4 --
Gadgeel et al., 2014 Alectinib ALK (II) 21 52 -- --
Gadgeel et al., 2016 Alectinib ALK (II) 136 42.6 11.1 --
Novello et al., 2018 (ALUR) Alectinib ALK (II) 40 54.2 -- --
Camidge et al, 2018 (ALTA) Brigatinib ALK (II) 59 46-67 14.6-18.4 --
Shaw et al., 2017 Lorlatinib ALK/ROS1 (III) 24 46 -- --
Solomon et al., 2018 Lorlatinib ALK/ROS1 (III) 165 53.1-87.0 -- --
Abbreviations: cRR: CNS response rate; gen: generation; mo: months; N: # patients; OS: overall survival; PFS: progression 
free survival; WBRT: whole-brain radiation therapy.
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patients with a specific EGFR mutation (T790M) who 
have failed prior tyrosine kinase inhibitor treatment [22]. 
Preclinical studies have shown good CNS penetration and 
activity of third-generation EGFR inhibitors [23], and 
additional clinical trials are underway (NCT02972333, 
NCT02736513, NCT02971501). The efficacy of second 
and third-generation EGFR inhibitors for the management 
of NSCLC BM requires further study before they can be 
recommended for clinical use.
ALK inhibitors
ALK-positive NSCLC make up approximately 5% 
of patients with NSCLC metastases and are characterized 
by a fusion of ALK and EML4 genes. These patients are 
of particular interest because they comprise primarily 
younger patients with little or no smoking history and 
for which EGFR inhibitors do not work [24, 25]. BM 
appear to be more common in patients with ALK-positive 
NSCLC compared to unselected NSCLC [9, 26]. Several 
notable ALK inhibitors have been studied with positive 
effects in ALK-positive NSCLC BM [27].
The first-generation ALK inhibitor, crizotinib, 
was approved in 2011 for treatment of patients with 
locally advanced or metastatic ALK-positive NSCLC. A 
retrospective analysis of two randomized clinical trials 
(PROFILE 1005 and 1007) examined the intracranial 
response to crizotinib in patients with ALK-positive 
NSCLC BM, and found intracranial disease control rates 
of 56-62% [28]. However, several studies have found CNS 
disease progression resulting from acquired resistance to 
crizotinib [29–31].
Subsequently, two second-generation ALK 
inhibitors, ceritinib and alectinib, were found to have 
improved CNS penetration and are now approved for 
the treatment of ALK-positive metastatic NSCLC in 
patients who previously failed crizotinib [9]. An open-
label phase I trial assessed the safety of ceritinib in 246 
patients (ASCEND-1), and efficacy was determined in 
post-hoc analysis [32]. In this trial, 94 (38%) patients had 
confirmed BM and follow-up neuroimaging. Intracranial 
disease control with ceritinib was 79% and 65% in ALK-
inhibitor naïve and previously ALK-inhibitor treated 
patients, respectively. Intracranial activity of ceritinib has 
been confirmed in several follow-up phase II/III studies 
(ASCEND 2-5) [33–35]. An open-label, multicenter phase 
II trial is ongoing to assess the safety and efficacy of 
ceritinib in patients with ALK-positive NSCLC and brain 
or leptomeningeal metastases (NCT02336451). At present, 
ceritinib appears to be effective in controlling BM from 
ALK-positive NSCLC and may be more beneficial when 
used prior to crizotinib.
Following the phase I trial for alectinib in patients 
with ALK-positive NSCLC, a multi-center, single-group, 
open-label phase II trial was undertaken in North America 
[36, 37]. All 87 patients in this trial had baseline CNS 
imaging with MRI or CT, and 16 (18%) had measurable 
CNS disease at baseline. Of these, 11 (69%) had received 
prior brain radiation therapy. Complete CNS response was 
reported in 4 of the 16 patients, and partial response in an 
additional 8 of 16. Median duration of CNS response was 
11.1 months. A global phase II trial assessing 138 patients 
with ALK-positive NSCLC who were treated with second-
line alectinib after failing crizotinib showed similar results 
[38]. A pooled analysis of these two trials included 225 
total patients, 136 (60%) of which had CNS metastases 
at baseline (50 measurable, 86 unmeasurable) [39]. All 
patients had been previously treated with crizotinib and 95 
(70%) had already undergone radiation therapy. Complete 
CNS response was seen in 37 (27.2%) patients, partial 
response in 21 (15.4%), and 58 (42.6%) patients had stable 
CNS disease. Median CNS duration of response was 
11.1 months.
Following the success of phase I and II trials for 
alectinib in ALK-positive NSCLC, several phase III 
studies focused on CNS disease [40–42]. The ALEX study 
included 122 patients with ALK-positive NSCLC and 
baseline BM who received either alectinib or crizonitib 
[43]. CNS response rate was 85.7% with alectinib versus 
71.4% with crizonitib in patients with prior radiotherapy 
and 78.6% versus 40.0%, respectively, in those without 
prior radiotherapy. The ALUR study randomized a total 
of 107 patients with advanced ALK-positive NSCLC who 
were previously treated with crizotinib to receive either 
alectinib or chemotherapy [40]. Out of the 40 patients 
with baseline measurable CNS disease (24 alectinib, 
16 chemotherapy), CNS response rate was higher with 
alectinib (54.2%) versus chemotherapy (0%). Together, 
these studies suggest robust response of ALK-positive 
NSCLC BM to alectinib both as initial and secondary 
ALK inhibitor therapy.
Another second-generation ALK-inhibitor, 
brigatinib, has shown promising intracranial disease 
activity in clinical trials [44, 45]. ALTA was a randomized 
phase II trial in which patients with ALK-positive NSCLC 
with baseline BM received varying doses of brigatinib 
[44]. Intracranial response rate among patients with 
measurable BM was 46-67% (total 59 patients). Median 
intracranial PFS was 14.6 to 18.4 months. Another 
open-label, randomized, phase III trial enrolled 275 
patients with advanced ALK-positive NSCLC who were 
ALK-inhibitor naïve to receive brigatinib or crizotinib 
[45]. Among 39 patients with measurable brain lesions, 
intracranial response rate was 14 out of 18 (78%) with 
brigatinib versus 6 out of 21 (29%) with crizotinib. 
Therefore, brigatinib has improved intracranial activity 
compared to crizotinib and is efficacious in the treatment 
of ALK-positive NSCLC BM.
Finally, promising data are emerging regarding a 
third-generation dual-inhibitor of ALK and ROS proto-
oncogene 1 (ROS1) with CNS penetrance, lorlatinib. 
An international multicenter, open-label phase I study 
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enrolled 54 patients with advanced ALK-positive or 
ROS1-positive NSCLC to receive lorlatinib at varying 
doses, including 24 with baseline measurable BM [46]. 
Of these, 11 of 24 had intracranial objective response 
to the treatment drug (7 complete, 4 partial). This was 
followed by a phase II study which included 276 patients 
with ALK- or ROS1-positive NSCLC who underwent 
treatment with lorlatinib [47]. Study patients were 
divided into 6 cohorts on the basis of ALK and ROS1 
status and previous therapy with crizotinib, other ALK-
inhibitors, or chemotherapy. In patients with measurable 
baseline BM, objective intracranial responses were 
noted in 53.1-87.0% of patients with ALK-positive 
NSCLC. Lorlatinib is currently undergoing a phase III 
trial comparing its efficacy against crizotinib as first-
line treatment for ALK-positive NSCLC (NCT02927340 
and NCT03052608). Overall, lorlatinib demonstrates 
strong activity against ALK-positive NSCLC BM 
and may also be efficacious for ROS1-positive 
NSCLC.
MELANOMA BRAIN METASTASES
The prevalence of BM in patients with malignant 
melanoma is as high as 50-75%, and survival of patients 
with multiple BM is generally 6 months or less [48–50]. 
Because patients with melanoma BM frequently have 
multiple small metastases, systemic targeted therapy is an 
attractive treatment option (Table 2) [9, 51, 52].
BRAF-inhibitors
The proto-oncogene BRAF is mutated in 
approximately 50% of malignant melanomas [53], and 
BRAF-mutant melanoma is associated with a higher rate 
of CNS involvement (24%) compared with BRAF wild 
type melanomas (12%) [54]. At present, two BRAF-
inhibitors, vemurafenib and dabrafenib, are approved for 
the treatment of advanced malignant melanoma. An open-
label phase II trial treated 24 patients with nonresectable, 
previously treated BRAF-mutated melanoma BM using 
vemurafenib [55]. In this cohort, median OS was 5.3 
months and PFS was 3.9 months. Among 19 patients 
with measurable intracranial disease at baseline, 3 (16%) 
experienced partial response and 13 (68%) had stable 
intracranial disease. Another multicenter, open-label phase 
II trial examined the response of BM from BRAF-mutated 
melanoma to vemurafenib [56]. The study included 90 
patients with previously untreated BM (cohort 1), and 56 
patients who had received prior treatment for their BM 
(cohort 2). Overall intracranial response rate was 16 out 
of 90 (18%) in cohort 1, including two complete responses 
and 14 partial responses. Median OS and PFS were 8.9 
and 3.7 months in cohort 1, respectively, and 9.6 and 4.0 
months in cohort 2, respectively. Together, these studies 
suggest a modest response of intracranial disease to 
vemurafenib in BRAF-mutant melanoma.
Use of dabrafenib to treat melanoma BM has been 
explored in a phase I trial involving 184 patients who 
received the drug for incurable solid tumors [57]. Out 
of 10 patients who had asymptomatic, untreated BM, 
9 had decrease in size of their BM, and 4 had complete 
resolution. Median PFS was 4.2 months in this subset 
of patients. A subsequent multicenter, open-label phase 
II trial included 172 patients with melanoma BM who 
were treated with dabrafenib [58]. Patients were divided 
by prior local treatment status and by type of BRAF-
mutation (BRAFV600E or BRAFV600K). Out of 74 patients 
with previously untreated BM and BRAFV600E mutations, 
29 (39.2%) had an overall intracranial response. Out of 65 
patients who had undergone prior local treatment for BM 
and had BRAFV600E mutations, 20 (30.8%) achieved overall 
intracranial response. OS and PFS were 33.1 and 16.1 
months, respectively, for untreated patients, and 31.4 and 
16.6 months, respectively, for previously treated patients. 
Response rates, OS, and PFS were lower in patients 
with BRAFV600K-mutant melanoma. Overall, dabrafenib 
has activity against BRAFV600E-mutant melanoma BM 
regardless of prior local treatment status.
BRAF- and MEK-inhibitor combination therapy
One major challenge in treating metastatic 
melanoma with BRAF-inhibitors is the 13 development 
of resistance secondary to upregulation of other proteins 
in the Ras-Raf-MEK14 MAPK pathway, such as RAF1 
(C-RAF) or RAS. This can lead to increased tumor cell 15 
proliferation and even to the development of secondary 
Table 2: Selected clinical studies of targeted treatments for melanoma brain metastases
Authors & Year Regimen Target N cRR (%) PFS (mo) OS (mo)
Dummer et al., 2014 Vemurafenib BRAF 24 84 3.9 5.3
McArthur et al., 2017 Vemurafenib BRAF 146 18 3.7-4.0 8.9-9.6
Falchook et al., 2012 Dabrafenib BRAF 10 90 4.2 --
Long et al., 2012 (BREAK-MB) Dabrafenib BRAFV600E 139 30.8-39.2 16.1-16.6 31.4-33.1
Davies et al., 2017 (COMBI-MB) Dabrafenib + trametinib BRAFV600E/MEK 76 58 5.6 10.8
Abbreviations: cRR: CNS response rate; mo: months; N: # patients; OS: overall survival; PFS: progression free survival
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skin tumors such as squamous cell 16 carcinomas [59–62]. 
This finding has led to trials combining treatment with 
BRAF-inhibitors and 17 the MEK-inhibitor, trametinib. 
An open-label phase III trial investigated the efficacy of 
18 dabrafenib and trametinib combination treatment in 
704 patients with BRAF-mutated metastatic 19 melanoma 
[63]. The study found that first-line combination 
dabrafenib-trametinib led to 20 improved 12 months OS 
(72% versus 65%) and longer median PFS (11.4 versus 
7.3 months) 21 compared to vemurafenib monotherapy. 
This was followed by a multicenter, open-label, phase II 
22 trial (COMBI-MB) that examined intracranial response 
to combination dabrafenib-trametinib in 23 patients with 
BRAF-mutant melanoma BM [64]. The study found 
intracranial response in 44 of 1376 (58%) patients, OS 
of 10.8 months, and PFS of 5.6 1 months in patients 
with BRAFV600E-2 mutant, asymptomatic BM with no 
prior local treatment. Overall, patients appear to benefit 
3 clinically from dabrafenib-trametinib as evidenced by 
median OS of 10.1-24.3 versus 3.4 months 4 in historical 
controls treated with WBRT alone.
BREAST CANCER BRAIN METASTASES
Breast cancer is the most common cancer in 
women, and 10-20% of breast cancer patients have BM 
[65, 66]. Breast cancers can be classified on the basis 
of estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2 (HER2) status. HER2 
overexpression is present in approximately 25-30% of 
breast cancers, and these are 2-4 times more likely to 
result in BM [9]. Thus far, only HER2-positive breast 
cancers have found success in targeted therapy for BM 
(Table 3) [67, 68].
Trastuzumab is a monoclonal humanized antibody 
directed against the extracellular domain of HER2 and is 
highly effective for the treatment of HER2-positive breast 
cancer [69–71]. Although trastuzumab cannot cross the 
intact BBB due to its large molecular size, studies have 
suggested trastuzumab penetration in BM secondary to 
BBB breakdown [72]. Retrospective studies have shown 
response of BM to intravenous trastuzumab [73], and 
prospective trials assessing the efficacy of trastuzumab 
in the treatment of HER2-positive breast cancer BM are 
underway (NCT02571530 and NCT01325207). Currently, 
however, evidence for the use of trastuzumab in the 
treatment of breast cancer BM is still accumulating.
Lapatinib is a small receptor tyrosine kinase 
inhibitor that interferes with both HER2 and EGFR 
signaling and is believed to cross the BBB, albeit to a 
limited extent in the commonly used dosing regimen [74]. 
An open-label, multicenter phase II trial included 242 
patients with HER2-positive breast cancer and BM who 
had been treated with trastuzumab and a combination of 
WBRT and SRS, followed by lapatinib [75]. CNS partial 
response was seen in 6% of patients, stable disease in 
37%, and progressive disease in 46%. There were no 
complete responses. OS in the study was 6.4 months and 
PFS was 2.4 months. An extension of the trial included 50 
patients who received additional treatment with lapatinib 
plus capecitabine, resulting in CNS partial response rate 
of 20% (no complete responses) and PFS of 3.7 months. 
The LANDSCAPE trial was an open-label, multicenter 
phase II trial that evaluated the response of radiation-
naïve HER2-positive breast cancer BM to first-line 
lapatinib-capecitabine [76]. Out of the total 45 patients, 
partial CNS responses were seen in 29 (66%), median OS 
was 17 months, and PFS was 5.5 months. Clinical trials 
investigating the efficacy of lapatinib in combination with 
WBRT or SRS for treatment of HER2-positive breast 
cancer BM are ongoing (NCT01622868). Two additional 
dual HER2 and EGFR inhibitors, afatinib and neratinib, 
are undergoing clinical trials for treatment of BM from 
HER2-positive breast cancer with promising results [77, 
78]. In summary, dual HER2 and EGFR inhibitors exhibit 
modest CNS activity and may be used in the management 
of HER2-positive breast cancer BM.
Trastuzumab emtansine (T-DM1) is an antibody-
drug conjugate of trastuzumab and the cytotoxic 
microtubule-inhibitor DM1 (also known as emtansine). 
This was approved for the treatment of metastatic HER2-
positive breast cancer based on the phase III EMILIA trial 
which compared T-DM1 with lapatinib plus capecitabine 
and found improved PFS, OS, and objective response rate 
for T-DM1 [79]. A subsequent retrospective analysis of 
the EMILIA trial looked at the response rates of patients 
with BM at baseline and found significantly longer OS 
in those treated with T-DM1 (26.8 months) compared 
to lapatinib-capecitabine (12.9 months) [80]. A study 
examining T-DM1 as primary systemic therapy for 
BM from HER2-positive breast cancer found clinical 
benefit for CNS disease in 5 of 10 patients [81]. T-DM1 
demonstrated CNS activity for HER2-positive breast 
cancer BM, but additional clinical studies are needed 
due to the small sample size and retrospective nature of 
existing evidence.
IMMUNE CHECKPOINT INHIBITORS
Cancer immunotherapy refers to the modulation 
of the host’s immune system to treat malignancies and 
includes the use of checkpoint inhibitors (anti-CTLA-4 
and anti-PD-1/PD-L1 antibodies) to amplify the patient’s 
own antitumor immune response [7]. Checkpoint 
inhibitors have previously shown strong efficacy in 
extracranial advanced melanoma and NSCLC. However, 
the intracranial immune response is highly regulated and 
most checkpoint inhibitor clinical trials have excluded 
patients with BM [82]. More recent studies have yielded 
promising results regarding the use of checkpoint 
inhibitors for treatment of melanoma and NSCLC BM, 
and additional trials are underway (Table 4) [51, 83].
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Anti-CTLA-4 antibody
Ipilimumab is a monoclonal antibody directed 
against CTLA-4, which is involved in downregulating 
cytotoxic T-cell production, and is approved for treatment 
of metastatic melanoma [84]. Systemic response rates 
in melanoma patients range from 11-21%, with better 
response reported in patients with BRAF wild-type 
melanoma with PD-L1 expression [85, 86]. Intracranial 
activity of ipilimumab was first described in a post hoc 
analysis of a phase III trial which included 82 patients 
with asymptomatic BM and found reduced mortality 
with the agent [87]. This was followed by an open-label 
phase II study of ipilimumab that included 72 patients 
(51 asymptomatic, 21 symptomatic) with melanoma BM 
[88]. Intracranial response was seen in 13 of 51 (25%) 
asymptomatic patients and two of 21 (10%) symptomatic 
patients. Median OS was 7.0 months in asymptomatic 
and 3.7 months in symptomatic patients. Another open-
label phase II trial administered combination ipilimumab-
fotemustine to patients with metastatic melanoma with 
and without CNS involvement (NIBIT-M1) [89]. The 
study included data on 20 patients with asymptomatic 
BM who had intracranial response rate of 10 out of 20 
(50%), median OS of 12.7 months, and PFS of 3.0 months. 
Following the optimistic results of the phase II trial, a 
phase III trial comparing fotemustine versus fotemustine-
ipilimumab versus ipilimumab-nivolumab in melanoma 
patients with BM is currently underway (NIBIT-M2, 
NCT02460068). In summary, the anti-CTLA-4 antibody 
ipilimumab has demonstrated efficacy against melanoma 
BM and additional data are accruing.
Anti-PD-1/PD-L1 antibodies
Nivolumab and pembrolizumab are anti-PD-1/PD-
L1 antibodies which have been approved for advanced 
melanoma and NSCLC [7]. They have been found to 
be superior to ipilimumab for advanced melanoma with 
systemic response rates ranging from 33-57%, but these 
studies excluded patients with BM [85, 90]. A recently 
completed single-center, phase II study of pembrolizumab 
enrolled melanoma and NSCLC patients with newly 
diagnosed asymptomatic or progressing BM who did 
not require immediate treatment with steroids. Among 
the 18 NSCLC patients, intracranial response rate was 
six (33%, four complete and two partial), and median 
OS was 7.7 months [91]. In the 23 melanoma patients, 
intracranial response rate was six (26%, four complete and 
two partial), OS was 17 months, and PFS was 2 months 
Table 3: Selected clinical studies of targeted treatments for HER2-positive breast cancer brain metastases
Authors & Year Regimen Target N cRR (%) PFS (mo) OS (mo)
Lin et al., 2009 Lapatinib +/- capecitabine HER2/EGFR 242 6-20 2.4-3.7 6.4
Bachelot et al., 2013 
(LANDSCAPE) Lapatinib + capecitabine HER2/EGFR 45 66 5.5 17
Freedman et al., 2019 Neratinib + capecitabine HER2/EGFR 49 33-49 3.1-5.5 13.3-15.1
Krop et al., 2015 (EMILIA) T-DM1 HER2 45 -- 5.9 26.8
Bartsch et al., 2015 T-DM1 HER2 10 50 5 --
Abbreviations: cRR: CNS response rate; mo: months; N: # patients; OS: overall survival; PFS: progression free survival; 
T-DM1: trastuzumab emtansine.
Table 4: Selected clinical studies of immune checkpoint inhibitors for brain metastases
Authors & Year Regimen Mechanism Primary cancer N cRR (%) PFS (mo) OS (mo)
Margolin et al., 2012 IPI CTLA-4 Melanoma 72 10-25 -- 3.7-7.0
Di Giacomo et al., 
2012 (NIBIT-M1) IPI + FTM CTLA-4 Melanoma 20 50 3.0 12.7
Kluger et al., 2019 Pembrolizumab PD-1/PD-L1 Melanoma 23 26 2 17
Goldberg et al., 2016 Pembrolizumab PD-1/PD-L1 NSCLC 18 33 -- 7.7
Tawbi et al., 2018 Nivolumab + IPI PD-1/PD-L1 + CTLA-4 Melanoma 94 55 -- --
Long et al., 2018 Nivolumab +/- IPI PD-1/PD-L1 +/- CTLA-4 Melanoma 76 6-46 2.3-NR 5.1-NR
Abbreviations: cRR: CNS response rate; FTM: fotemustine; IPI: ipilimumab; mo: months; N: # patients; NR: not reached; 
OS: overall survival; PFS: progression free survival.
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[92]. Another multicenter phase II trial of ipilimumab-
nivolumab included data on 94 patients with advanced 
melanoma and asymptomatic BM [93]. This study found 
intracranial response rate of 55% (24 complete, 28 partial 
responses). Finally, a multicenter, open-label, randomized 
phase II trial reported on 60 patients with melanoma and 
asymptomatic BM with no previous local therapy who 
received ipilimumab-nivolumab (cohort A) or nivolumab 
alone (cohort B) [94]. The study also included 16 patients 
with BM who had neurological symptoms, leptomeningeal 
disease, or local therapy failure and underwent therapy 
with nivolumab alone (cohort C). Intracranial response 
rates were 16 of 35 (46%) in cohort A, five of 25 (20%) 
in cohort B, and one of 16 (6%) in cohort C. Median OS 
was not yet reached in cohort A, was 18.5 months in B, 
and was 5.1 months in C. Median intracranial PFS was 
not reached in cohort A, was 2.5 months in B, and was 
2.3 months in C. Overall, the anti-PD-1/PD-L1 antibodies, 
nivolumab and pembrolizumab, appear to be effective 
in treating intracranial manifestations of metastatic 
melanoma; pembrolizumab may also be efficacious in 
managing NSCLC BM.
Predicting response to immune checkpoint 
inhibitors
The identification of biomarkers to predict response 
to immune checkpoint inhibitors has been explored in 
recent years. Histopathological studies have demonstrated 
critical links between tumor-infiltrating immune cell 
density and distribution, PD-1 expression in immune cells, 
and PD-L1 expression in tumor cells with overall disease 
prognosis in patients with lung cancer and melanoma BM 
[82, 95–97]. For instance, high tumor PD-L1 expression 
has been widely explored as a potential predictive 
biomarker for selecting patients who will derive benefit 
from anti-PD-1/PD-L1 therapy in primary NSCLC and 
melanoma, but studies have not specifically focused on 
BM [98, 99]. Furthermore, interferon-γ is an important 
regulator of immunity that is produced by natural killer 
and activated T-cells and induces PD-L1 expression as 
an adaptive response to endogenous antitumor immunity 
in numerous primary extracranial cancer cells, as well as 
in multiple components of the glioma microenvironment 
[100, 101]. Expression of interferon-γ and interferon-γ-
inducible genes correlate with response to anti-PD-1/
PD-L1 agents in primary melanoma and NSCLC: patients 
with both interferon-γ and PD-L1-positivity (as defined 
by greater than 25% of tumor cells) demonstrated the 
highest response rates [100, 102, 103]. Additionally, high 
somatic mutational burden as characterized by whole-
exome sequencing or various next generation sequencing 
panels has been correlated with sustained clinical benefit 
from immune checkpoint inhibitors in a growing number 
of extracranial cancers including melanoma, NSCLC, 
urothelial cancer, and head and neck squamous cell 
carcinoma [104–107]. Both FoundationOne CDx and 
MSK-IMPACT sequencing panels have been approved 
by the FDA for measurement of tumor mutational burden 
[108]. Finally, studies have suggested that activation of 
the Ras-MAPK pathway may be a useful biomarker for 
predicting response to immune checkpoint inhibitors 
[109–111]. In general, although these biomarkers show 
promise in primary NSCLC and melanoma, additional 
studies validating their ability to predict response to 
immunotherapy specifically in intracranial disease are 
still needed.
IMPLICATIONS FOR PRACTICE AND 
FUTURE DIRECTIONS
For targeted agents and immune checkpoint 
inhibitors, baseline MRI should be performed within a 
month prior to initiating treatment, followed by an image 
approximately every two to three months for the first year 
and an increasing interval thereafter. This interval has 
not been studied rigorously, but allows early detection 
of treatment failure and switching to more traditional 
therapies if indicated.
To assess patients receiving immunotherapy, 
the immunotherapy Response Assessment for Neuro-
Oncology (iRANO) criteria were developed [112]. 
Importantly, if the contrast-enhanced MRI suggests 
progression within the first 6 months of treatment, there 
should be a confirmation image before stopping therapy. 
The goal of this recommendation is to allow for the 
possibility that significant enhancement may reflect an 
inflammatory response to the tumor, and an efficacious 
response. Waiting for this confirmatory MRI, optimally 
up to three months later, is dependent on the patient 
being clinically stable. This is a complicated point, as 
advancing symptoms may be secondary to a worsening 
brain lesion, regardless of the etiology being anti-tumor 
inflammation or tumor progression. Another point is 
that after treatment with immunotherapy, new enhancing 
lesions may appear as a result of anti-tumor responses 
against previously unknown but present lesions that were 
not detected on MRI. In this case, new changes on an 
MRI reflect response and not treatment failure. Lastly, if 
there has been a decrease in steroids within two weeks 
of MRI, the MRI-detected lesion cannot necessarily be 
called progressive, but rather non-evaluable. Patients with 
significant changes by iRANO criteria after 6 months 
of initiating immunotherapy are considered as no longer 
deriving benefit.
MRI sequences such as perfusion and cerebral 
blood volume are used in some centers to try to 
distinguish between inflammation and tumor progression, 
but there is little validation data published. PET/MRI is 
another potentially useful tool. A hypometabolic lesion 
on PET/MRI increases the confidence that the change 
is less likely tumor progression; however, there are not 
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yet norms to define how much avidity inflammatory 
responses may have.
Finally, additional phase 0 trials are needed to 
test whether targeted systemic therapies are penetrating 
BM. These trials would involve upfront treatment with 
targeted agents followed by surgical resection and ideally 
both determination of drug concentration and evidence 
of “on-target” activity within resected tissue. Such trials 
could have the additional benefit of validating surrogate 
response biomarkers, which would optimally be less 
invasive than needle biopsy or surgical resection.
CONCLUSIONS
Local treatment with surgery, SRS, and WBRT 
remain the mainstays of therapy for BM, but emerging 
evidence regarding the efficacy of targeted systemic 
treatments and immunotherapy continues to accumulate. 
For NSCLC, numerous clinical trials have demonstrated 
CNS activity for inhibitors of EGFR and ALK. Systemic 
therapy using BRAF-inhibitors with and without 
trametinib has resulted in encouraging outcomes for 
patients with melanoma BM. Several targeted options 
are available for breast cancer BM that overexpress 
HER2. Immune checkpoint inhibitors including anti-
CTLA-4 and anti-PD-1/PD-L1 antibodies are yielding 
impressive responses in melanoma and NSCLC BM. 
Management of eligible patients will require increased 
multidisciplinary discussion incorporating novel 
systemic treatment approaches prior or in addition to 
local therapy. In these cases, close follow-up with CNS 
imaging is necessary to evaluate response to targeted 
agents, with surgery or radiation as alternatives at 
disease progression.
Author contributions
R.H.H. and A.H.K. were involved in conception and 
design of the article. R.H.H. drafted the article. All authors 
critically revised and reviewed the submitted version of 
the manuscript. A.H.K. performed study supervision.
CONFLICTS OF INTEREST
A.H.K. received research grants from Monteris 
Medical and Stryker, which have no direct relation with 
this study. G.P.D. is a co-founder of Immunovalent, which 
is unrelated to this study. MGC receives royalties from 
UpToDate and research support from Neoimmunetech, 
which do not have direct relation to this study.
FUNDING
This work was in part funded by the Christopher 
Davidson and Knight Family Fund as well as the 
Duesenberg Research Fund (both to A.H.K.). This work 
was partly supported by National Institute of Neurological 
Disorders and Stroke of the National Institutes of Health 
(NIH) under award number R01NS107833 (M.G.C.). The 
content is solely the responsibility of the authors and does 
not necessarily represent the official views of the National 
Institutes of Health.
REFERENCES
1. Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow 
LQ. Systemic therapy of brain metastases: non-small cell 
lung cancer, breast cancer, and melanoma. Neuro Oncol. 
2017; 19:i1–i24. https://doi.org/10.1093/neuonc/now197. 
[PubMed]
2. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama 
Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. 
A randomized trial of surgery in the treatment of single 
metastases to the brain. N Engl J Med. 1990; 322:494–500. 
https://doi.org/10.1056/NEJM199002223220802. [PubMed]
3. Elder JB, Nahed BV, Linskey ME, Olson JJ. Congress 
of Neurological Surgeons Systematic Review and 
Evidence-Based Guidelines on the Role of Emerging and 
Investigational Therapties for the Treatment of Adults With 
Metastatic Brain Tumors. Neurosurgery. 2019; 84:E201–E3. 
https://doi.org/10.1093/neuros/nyy547. [PubMed]
4. Nahed BV, Alvarez-Breckenridge C, Brastianos PK, Shih 
H, Sloan A, Ammirati M, Kuo JS, Ryken TC, Kalkanis SN, 
Olson JJ. Congress of Neurological Surgeons Systematic 
Review and Evidence-Based Guidelines on the Role of 
Surgery in the Management of Adults With Metastatic 
Brain Tumors. Neurosurgery. 2019; 84:E152–E5. 
https://doi.org/10.1093/neuros/nyy542. [PubMed]
5. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura 
D, Jain RK. The biology of brain metastases-translation 
to new therapies. Nat Rev Clin Oncol. 2011; 8:344–56. 
https://doi.org/10.1038/nrclinonc.2011.58. [PubMed]
6. Shonka N, Venur VA, Ahluwalia MS. Targeted Treatment of 
Brain Metastases. Curr Neurol Neurosci Rep. 2017; 17:37. 
https://doi.org/10.1007/s11910-017-0741-2. [PubMed]
7. Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. 
Immune Checkpoint Inhibitors in Brain Metastases: From 
Biology to Treatment. Am Soc Clin Oncol Educ Book. 
2016; 35:e116–22. https://doi.org/10.14694/EDBK_100005. 
[PubMed]
8. Liao BC, Lin CC, Yang JC. Second and third-
generation epidermal growth factor receptor 
tyrosine kinase inhibitors in advanced nonsmall cell 
lung cancer. Curr Opin Oncol. 2015; 27:94–101. 
https://doi.org/10.1097/CCO.0000000000000164. [PubMed]
9. Di Lorenzo R, Ahluwalia MS. Targeted therapy 
of brain metastases: latest evidence and clinical 
implications. Ther Adv Med Oncol. 2017; 9:781–96. 
https://doi.org/10.1177/1758834017736252. [PubMed]
Oncotarget6748www.oncotarget.com
10. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. 
Brain metastases in adenocarcinoma of the lung: frequency, 
risk groups, and prognosis. J Clin Oncol. 1988; 6:1474–80. 
https://doi.org/10.1200/JCO.1988.6.9.1474. [PubMed]
11. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai 
P, Sawaya RE. Incidence proportions of brain metastases 
in patients diagnosed (1973 to 2001) in the Metropolitan 
Detroit Cancer Surveillance System. J Clin Oncol. 2004; 
22:2865–72. https://doi.org/10.1200/JCO.2004.12.149. 
[PubMed]
12. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-
sensitizing EGFR mutations in lung cancer activate 
anti-apoptotic pathways. Science. 2004; 305:1163–7. 
https://doi.org/10.1126/science.1101637. [PubMed]
13. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, 
Lee JS. Efficacy of epidermal growth factor receptor 
tyrosine kinase inhibitors for brain metastasis in non-
small cell lung cancer patients harboring either exon 
19 or 21 mutation. Lung Cancer. 2012; 77:556–60. 
https://doi.org/10.1016/j.lungcan.2012.05.092. [PubMed]
14. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-
Wasik M, Komaki R, Souhami L, Buyyounouski MK, 
Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G 
et al. A phase 3 trial of whole brain radiation therapy and 
stereotactic radiosurgery alone versus WBRT and SRS with 
temozolomide or erlotinib for non-small cell lung cancer 
and 1 to 3 brain metastases: Radiation Therapy Oncology 
Group 0320. Int J Radiat Oncol Biol Phys. 2013; 85:1312–
8. https://doi.org/10.1016/j.ijrobp.2012.11.042. [PubMed]
15. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh 
C, Lee JS. Epidermal growth factor receptor tyrosine 
kinase inhibitors as a first-line therapy for never-smokers 
with adenocarcinoma of the lung having asymptomatic 
synchronous brain metastasis. Lung Cancer. 2009; 65:351–
4. https://doi.org/10.1016/j.lungcan.2008.12.011. [PubMed]
16. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, 
Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki 
K, Iizasa T. Phase II trial of gefitinib alone without radiation 
therapy for Japanese patients with brain metastases from 
EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013; 
82:282–7. https://doi.org/10.1016/j.lungcan.2013.08.016. 
[PubMed]
17. Lee SM, Lewanski CR, Counsell N, Ottensmeier C, 
Bates A, Patel N, Wadsworth C, Ngai Y, Hackshaw A, 
Faivre-Finn C. Randomized trial of erlotinib plus whole-
brain radiotherapy for NSCLC patients with multiple 
brain metastases. J Natl Cancer Inst. 2014; 106:dju151.  
https://doi.org/10.1093/jnci/dju151. [PubMed]
18. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA, 
Jr. ZD1839, a selective epidermal growth factor receptor 
tyrosine kinase inhibitor, alone and in combination with 
radiation and chemotherapy as a new therapeutic strategy in 
non-small cell lung cancer. Semin Oncol. 2002; 29:37–46. 
https://doi.org/10.1053/sonc.2002.31521. [PubMed]
19. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 
(‘Iressa’), a specific oral epidermal growth factor receptor-
tyrosine kinase inhibitor, potentiates radiotherapy in a 
human colorectal cancer xenograft model. Br J Cancer. 
2002; 86:1157–61. https://doi.org/10.1038/sj.bjc.6600182. 
[PubMed]
20. Welsh JW, Komaki R, Amini A, Munsell MF, Unger 
W, Allen PK, Chang JY, Wefel JS, McGovern SL, 
Garland LL, Chen SS, Holt J, Liao Z et al. Phase II 
trial of erlotinib plus concurrent whole-brain radiation 
therapy for patients with brain metastases from non-
small-cell lung cancer. J Clin Oncol. 2013; 31:895–902. 
https://doi.org/10.1200/JCO.2011.40.1174. [PubMed]
21. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, 
Schutz M, Serke M, Stohlmacher-Williams J, Marten A, 
Maria Huber R, Dickgreber NJ Afatinib Compassionate 
Use C. Efficacy of the irreversible ErbB family blocker 
afatinib in epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor (TKI)-pretreated non-small-
cell lung cancer patients with brain metastases or 
leptomeningeal disease. J Thorac Oncol. 2015; 10:156–63. 
https://doi.org/10.1097/JTO.0000000000000380. [PubMed]
22. Greig SL. Osimertinib: First Global Approval. Drugs. 2016; 
76:263–73. https://doi.org/10.1007/s40265-015-0533-4. 
[PubMed]
23. Zeng Q, Wang J, Cheng Z, Chen K, Johnstrom P, 
Varnas K, Li DY, Yang ZF, Zhang X. Discovery 
and Evaluation of Clinical Candidate AZD3759, 
a Potent, Oral Active, Central Nervous System-
Penetrant, Epidermal Growth Factor Receptor Tyrosine 
Kinase Inhibitor. J Med Chem. 2015; 58:8200–15. 
https://doi.org/10.1021/acs.jmedchem.5b01073. [PubMed]
24. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy 
SR, Costa DB, Heist RS, Solomon B, Stubbs H, 
Admane S, McDermott U, Settleman J, Kobayashi 
S, Mark EJ et al. Clinical features and outcome of 
patients with non-small-cell lung cancer who harbor 
EML4-ALK. J Clin Oncol. 2009; 27:4247–53. 
https://doi.org/10.1200/JCO.2009.22.6993. [PubMed]
25. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng 
LC, Ho KK, Au JS, Chung LP, Pik Wong M University of 
Hong Kong Lung Cancer Study G. The EML4-ALK fusion 
gene is involved in various histologic types of lung cancers 
from nonsmokers with wild-type EGFR and KRAS. Cancer. 
2009; 115:1723–33. https://doi.org/10.1002/cncr.24181. 
[PubMed]
26. Rangachari D, Yamaguchi N, VanderLaan PA, Folch 
E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, 
Dahlberg SE, Huberman MS, Costa DB. Brain metastases 
in patients with EGFR-mutated or ALK-rearranged non-
small-cell lung cancers. Lung Cancer. 2015; 88:108–11. 
https://doi.org/10.1016/j.lungcan.2015.01.020. [PubMed]
27. Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, 
Metro G, Baglivo S, Sidoni A, Bellezza G, Crino L, Chiari 
Oncotarget6749www.oncotarget.com
R. Precision medicine against ALK-positive non-small cell 
lung cancer: beyond crizotinib. Med Oncol. 2018; 35:72. 
https://doi.org/10.1007/s12032-018-1133-4. [PubMed]
28. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely 
GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli 
A, Schnell P, Wilner KD, Wiltshire R et al. Clinical 
Experience With Crizotinib in Patients With Advanced 
ALK-Rearranged Non-Small-Cell Lung Cancer and 
Brain Metastases. J Clin Oncol. 2015; 33:1881–8. 
https://doi.org/10.1200/JCO.2014.59.0539. [PubMed]
29. Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD. 
Isolated central nervous system progression on Crizotinib: 
an Achilles heel of non-small cell lung cancer with EML4-
ALK translocation? Cancer Biol Ther. 2012; 13:1376–83. 
https://doi.org/10.4161/cbt.22255. [PubMed]
30. Maillet D, Martel-Lafay I, Arpin D, Perol M. 
Ineffectiveness of crizotinib on brain metastases 
in two cases of lung adenocarcinoma with EML4-
ALK rearrangement. J Thorac Oncol. 2013; 8:e30–1. 
https://doi.org/10.1097/JTO.0b013e318288dc2d. [PubMed]
31. Takeda M, Okamoto I, Nakagawa K. Clinical impact of 
continued crizotinib administration after isolated central 
nervous system progression in patients with lung cancer 
positive for ALK rearrangement. J Thorac Oncol. 2013; 
8:654–7. https://doi.org/10.1097/JTO.0b013e31828c28e7. 
[PubMed]
32. Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, 
Camidge DR, Vansteenkiste J, Sharma S, De Pas 
T, Riely GJ, Solomon BJ, Wolf J, Thomas M et al. 
Activity and safety of ceritinib in patients with ALK-
rearranged non-small-cell lung cancer (ASCEND-1): 
updated results from the multicentre, open-label, 
phase 1 trial. Lancet Oncol. 2016; 17:452–63. 
https://doi.org/10.1016/S1470-2045(15)00614-2. [PubMed]
33. Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida 
T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle 
F, Emeremni C et al. Multicenter Phase II Study of Whole-
Body and Intracranial Activity With Ceritinib in Patients 
With ALK-Rearranged Non-Small-Cell Lung Cancer 
Previously Treated With Chemotherapy and Crizotinib: 
Results From ASCEND-2. J Clin Oncol. 2016; 34:2866–73. 
https://doi.org/10.1200/JCO.2015.65.5936. [PubMed]
34. Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu 
G, Novello S, Bearz A, Gautschi O, Mok T, Nishio 
M, Scagliotti G, Spigel DR et al. Ceritinib versus 
chemotherapy in patients with ALK-rearranged non-
small-cell lung cancer previously given chemotherapy 
and crizotinib (ASCEND-5): a randomised, controlled, 
open-label, phase 3 trial. Lancet Oncol. 2017; 18:874–86. 
https://doi.org/10.1016/S1470-2045(17)30339-X. [PubMed]
35. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf 
J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair 
M, Cortot AB, Tsai CM et al. First-line ceritinib versus 
platinum-based chemotherapy in advanced ALK-rearranged 
non-small-cell lung cancer (ASCEND-4): a randomised, 
open-label, phase 3 study. Lancet. 2017; 389:917–29. 
https://doi.org/10.1016/S0140-6736(17)30123-X. [PubMed]
36. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, 
West HL, Azada MC, Morcos PN, Lee RM, Garcia 
L, Yu L, Boisserie F, Di Laurenzio L, Golding S et 
al. Safety and activity of alectinib against systemic 
disease and brain metastases in patients with crizotinib-
resistant ALK-rearranged non-small-cell lung cancer 
(AF-002JG): results from the dose-finding portion of 
a phase 1/2 study. Lancet Oncol. 2014; 15:1119–28. 
https://doi.org/10.1016/S1470-2045(14)70362-6. [PubMed]
37. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, 
West H, Camidge DR, Socinski MA, Chiappori A, 
Mekhail T, Chao BH, Borghaei H, Gold KA et al. 
Alectinib in ALK-positive, crizotinib-resistant, non-
small-cell lung cancer: a single-group, multicentre, 
phase 2 trial. Lancet Oncol. 2016; 17:234–42. 
https://doi.org/10.1016/S1470-2045(15)00488-X. [PubMed]
38. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes 
B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail 
T, Spira A, Bordogna W et al. Alectinib in Crizotinib-
Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: 
A Phase II Global Study. J Clin Oncol. 2016; 34:661–8. 
https://doi.org/10.1200/JCO.2015.63.9443. [PubMed]
39. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski 
MA, Camidge DR, De Petris L, Kim DW, Chiappori A, 
Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T et 
al. Pooled Analysis of CNS Response to Alectinib in Two 
Studies of Pretreated Patients With ALK-Positive Non-
Small-Cell Lung Cancer. J Clin Oncol. 2016; 34:4079–85. 
https://doi.org/10.1200/jco.2016.68.4639. [PubMed]
40. Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, 
Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter 
A, Cardona A, Balas B, Johannsdottir HK et al. Alectinib 
versus chemotherapy in crizotinib-pretreated anaplastic 
lymphoma kinase (ALK)-positive non-small-cell lung 
cancer: results from the phase III ALUR study. Ann Oncol. 
2018; 29:1409–16. https://doi.org/10.1093/annonc/mdy121. 
[PubMed]
41. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, 
Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, 
Zeaiter A, Mitry E, Golding S et al. Alectinib versus 
Crizotinib in Untreated ALK-Positive Non-Small-
Cell Lung Cancer. N Engl J Med. 2017; 377:829–38. 
https://doi.org/10.1056/NEJMoa1704795. [PubMed]
42. Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib 
in ALK-positive lung cancer. Lancet. 2017; 390:3–4. 
https://doi.org/10.1016/s0140-6736(17)31074-7. [PubMed]
43. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou 
SI, Perol M, Wrona A, Novello S, Rosell R, Zeaiter 
A, Liu T, Nuesch E et al. Alectinib versus crizotinib in 
treatment-naive anaplastic lymphoma kinase-positive 
(ALK+) non-small-cell lung cancer: CNS efficacy results 
from the ALEX study. Ann Oncol. 2018; 29:2214–22. 
https://doi.org/10.1093/annonc/mdy405. [PubMed]
Oncotarget6750www.oncotarget.com
44. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw 
AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold 
KA, Ou SI, West HL et al. Exploratory Analysis of Brigatinib 
Activity in Patients With Anaplastic Lymphoma Kinase-
Positive Non-Small-Cell Lung Cancer and Brain Metastases 
in Two Clinical Trials. J Clin Oncol. 2018; 36:2693–701. 
https://doi.org/10.1200/jco.2017.77.5841. [PubMed]
45. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee 
JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli 
C, Delmonte A, Garcia Campelo R et al. Brigatinib 
versus Crizotinib in ALK-Positive Non-Small-Cell 
Lung Cancer. N Engl J Med. 2018; 379:2027–39. 
https://doi.org/10.1056/NEJMoa1810171. [PubMed]
46. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-
Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, 
Clancy JS, Chen J, Martini JF et al. Lorlatinib in non-
small-cell lung cancer with ALK or ROS1 rearrangement: 
an international, multicentre, open-label, single-arm first-
in-man phase 1 trial. Lancet Oncol. 2017; 18:1590–9. 
https://doi.org/10.1016/s1470-2045(17)30680-0. [PubMed]
47. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, 
Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, 
Riely GJ, Tan EH, Seto T et al. Lorlatinib in patients with 
ALK-positive non-small-cell lung cancer: results from a 
global phase 2 study. Lancet Oncol. 2018; 19:1654–67. 
https://doi.org/10.1016/s1470-2045(18)30649-1. [PubMed]
48. Davies MA. Targeted therapy for brain 
metastases. Adv Pharmacol. 2012; 65:109–42. 
https://doi.org/10.1016/B978-0-12-397927-8.00005-1. [PubMed]
49. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos 
NE, Hwu WJ, Homsi J, Davies M, McIntyre S, 
Hwu P. Predictive factors for the development of 
brain metastasis in advanced unresectable metastatic 
melanoma. Am J Clin Oncol. 2011; 34:603–10. 
https://doi.org/10.1097/COC.0b013e3181f9456a. [PubMed]
50. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, 
Shannon KF, Harman R, Petersen-Schaefer K, Zacest 
AC, Besser M, Milton GW, McCarthy WH, Thompson 
JF. Determinants of outcome in melanoma patients with 
cerebral metastases. J Clin Oncol. 2004; 22:1293–300. 
https://doi.org/10.1200/JCO.2004.08.140. [PubMed]
51. Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP, 
Dunn IF. Management of intracranial melanomas in the 
era of precision medicine. Oncotarget. 2017; 8:89326–47. 
https://doi.org/10.18632/oncotarget.19223. [PubMed]
52. Ramanujam S, Schadendorf D, Long GV. Systemic 
therapies for melanoma brain metastases: which drug 
for whom and when? Chin Clin Oncol. 2015; 4:25. 
https://doi.org/10.3978/j.issn.2304-3865.2015.06.06. [PubMed]
53. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg 
S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis 
N, Dicks E, Ewing R et al. Mutations of the BRAF gene 
in human cancer. Nature. 2002; 417:949–54. https://doi.
org/10.1038/nature00766. [PubMed]
54. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, 
Alvarado GC, Rohlfs ML, Richard J, Gershenwald 
JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS 
mutation status is an independent prognostic factor 
in metastatic melanoma. Cancer. 2012; 118:4014–23. 
https://doi.org/10.1002/cncr.26724. [PubMed]
55. Dummer R, Goldinger SM, Turtschi CP, Eggmann 
NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, 
Felderer L, Rinderknecht JD. Vemurafenib in patients 
with BRAF(V600) mutation-positive melanoma with 
symptomatic brain metastases: final results of an open-
label pilot study. Eur J Cancer. 2014; 50:611–21. 
https://doi.org/10.1016/j.ejca.2013.11.002. [PubMed]
56. McArthur GA, Maio M, Arance A, Nathan P, Blank 
C, Avril MF, Garbe C, Hauschild A, Schadendorf D, 
Hamid O, Fluck M, Thebeau M, Schachter J et al. 
Vemurafenib in metastatic melanoma patients with 
brain metastases: an open-label, single-arm, phase 
2, multicentre study. Ann Oncol. 2017; 28:634–41. 
https://doi.org/10.1093/annonc/mdw641. [PubMed]
57. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau 
TH, Brown MP, Hamid O, Infante JR, Millward M, 
Pavlick AC, O'Day SJ, Blackman SC, Curtis CM et 
al. Dabrafenib in patients with melanoma, untreated 
brain metastases, and other solid tumours: a phase 1 
dose-escalation trial. Lancet. 2012; 379:1893–901. 
https://doi.org/10.1016/S0140-6736(12)60398-5. [PubMed]
58. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, 
Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, 
Mortier L, Tawbi H, Wilhelm T et al. Dabrafenib in patients 
with Val600Glu or Val600Lys BRAF-mutant melanoma 
metastatic to the brain (BREAK-MB): a multicentre, open-
label, phase 2 trial. Lancet Oncol. 2012; 13:1087–95. 
https://doi.org/10.1016/S1470-2045(12)70431-X. [PubMed]
59. Solit DB, Rosen N. Resistance to BRAF inhibition 
in melanomas. N Engl J Med. 2011; 364:772–4. 
https://doi.org/10.1056/NEJMcibr1013704. [PubMed]
60. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss 
O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, 
Chapman PB, Kim MJ, Hayward R et al. RAS mutations 
in cutaneous squamous-cell carcinomas in patients treated 
with BRAF inhibitors. N Engl J Med. 2012; 366:207–15. 
https://doi.org/10.1056/NEJMoa1105358. [PubMed]
61. Oberholzer PA, Kee D, Dziunycz P, Sucker A, 
Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, 
Palescandolo E, Piris A, MacConaill LE, Robert C et 
al. RAS mutations are associated with the development 
of cutaneous squamous cell tumors in patients treated 
with RAF inhibitors. J Clin Oncol. 2012; 30:316–21. 
https://doi.org/10.1200/JCO.2011.36.7680. [PubMed]
62. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau 
G, Chodon T, Guo R, Johnson DB, Dahlman KB, 
Kelley MC, Kefford RF, Chmielowski B et al. Acquired 
resistance and clonal evolution in melanoma during 
Oncotarget6751www.oncotarget.com
BRAF inhibitor therapy. Cancer Discov. 2014; 4:80–93. 
https://doi.org/10.1158/2159-8290.CD-13-0642. [PubMed]
63. Robert C, Karaszewska B, Schachter J, Rutkowski P, 
Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer 
R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, 
Krajsova I et al. Improved overall survival in melanoma 
with combined dabrafenib and trametinib. N Engl J Med. 
2015; 372:30–9. https://doi.org/10.1056/NEJMoa1412690. 
[PubMed]
64. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, 
Arance A, Chiarion-Sileni V, Thomas L, Lesimple 
T, Mortier L, Moschos SJ, Hogg D, Marquez-Rodas 
I et al. Dabrafenib plus trametinib in patients with 
BRAF(V600)-mutant melanoma brain metastases 
(COMBI-MB): a multicentre, multicohort, open-
label, phase 2 trial. Lancet Oncol. 2017; 18:863–73. 
https://doi.org/10.1016/S1470-2045(17)30429-1. [PubMed]
65. Chang EL, Lo S. Diagnosis and management 
of central nervous system metastases from 
breast cancer. Oncologist. 2003; 8:398–410. 
https://doi.org/10.1634/theoncologist.8-5-398. [PubMed]
66. Lassman AB, DeAngelis LM. Brain 
metastases. Neurol Clin. 2003; 21:1–23. vii. 
https://doi.org/10.1016/S0733-8619(02)00035-X. [PubMed] 
67. Harbeck N, Luftner D, Marschner N, Untch M, 
Augustin D, Briest S, Ettl J, Haidinger R, Muller L, 
Muller V, Ruckhaberle E, Wuerstlein R, Thomssen C. 
ABC4 Consensus: Assessment by a German Group 
of Experts. Breast Care (Basel). 2018; 13:48–58. 
https://doi.org/10.1159/000486722. [PubMed]
68. Venur VA, Leone JP. Targeted Therapies for Brain 
Metastases from Breast Cancer. Int J Mol Sci. 2016; 
17:1543. https://doi.org/10.3390/ijms17091543. [PubMed]
69. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin 
S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, 
Lichinitser M, Climent MA, Ciruelos E, Ojeda B et al. 
Neoadjuvant and adjuvant trastuzumab in patients with 
HER2-positive locally advanced breast cancer (NOAH): 
follow-up of a randomised controlled superiority trial with 
a parallel HER2-negative cohort. Lancet Oncol. 2014; 
15:640–7. https://doi.org/10.1016/S1470-2045(14)70080-4. 
[PubMed]
70. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, 
Jr. Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman 
PA, Swain SM, Pisansky TM, Fehrenbacher L et al. 
Trastuzumab plus adjuvant chemotherapy for operable 
HER2-positive breast cancer. N Engl J Med. 2005; 
353:1673–84. https://doi.org/10.1056/NEJMoa052122. 
[PubMed]
71. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, 
Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, 
Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH 
et al. Trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer. N Engl J Med. 2005; 353:1659–72. 
https://doi.org/10.1056/NEJMoa052306. [PubMed]
72. Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto 
J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada 
Y, Kodaira M, Yunokawa M, Yamamoto H et al. (64)
Cu-DOTA-trastuzumab PET imaging and HER2 specificity 
of brain metastases in HER2-positive breast cancer patients. 
EJNMMI Res. 2015; 5:8. https://doi.org/10.1186/s13550-
015-0082-6. [PubMed]
73. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, 
Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, 
Zielinski CC, Steger GG. Trastuzumab prolongs overall 
survival in patients with brain metastases from Her2 
positive breast cancer. J Neurooncol. 2007; 85:311–7. 
https://doi.org/10.1007/s11060-007-9420-5. [PubMed]
74. Medina PJ, Goodin S. Lapatinib: a dual inhibitor 
of human epidermal growth factor receptor 
tyrosine kinases. Clin Ther. 2008; 30:1426–47. 
https://doi.org/10.1016/j.clinthera.2008.08.008. [PubMed]
75. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, 
Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl 
S, Gori S, Wardley A et al. Multicenter phase II study of 
lapatinib in patients with brain metastases from HER2-
positive breast cancer. Clin Cancer Res. 2009; 15:1452–9. 
https://doi.org/10.1158/1078-0432.CCR-08-1080. [PubMed]
76. Bachelot T, Romieu G, Campone M, Dieras V, Cropet 
C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, 
Goncalves A, Leheurteur M, Domont J, Gutierrez 
M et al. Lapatinib plus capecitabine in patients with 
previously untreated brain metastases from HER2-positive 
metastatic breast cancer (LANDSCAPE): a single-
group phase 2 study. Lancet Oncol. 2013; 14:64–71. 
https://doi.org/10.1016/S1470-2045(12)70432-1. [PubMed]
77. Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, 
Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, 
Nabholtz JM, Kellokumpu-Lehtinen PL, et al. Afatinib 
alone or afatinib plus vinorelbine versus investigator's 
choice of treatment for HER2-positive breast cancer with 
progressive brain metastases after trastuzumab, lapatinib, 
or both (LUX-Breast 3): a randomised, open-label, 
multicentre, phase 2 trial. Lancet Oncol. 2015; 16:1700–
10. https://doi.org/10.1016/s1470-2045(15)00373-3. 
[PubMed]
78. Freedman RA, Gelman RS, Anders CK, Melisko 
ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, 
Componeschi KP, Marte JM, Connolly RM, Moy B, Van 
Poznak CH, et al. TBCRC 022: A Phase II Trial of Neratinib 
and Capecitabine for Patients With Human Epidermal 
Growth Factor Receptor 2-Positive Breast Cancer and 
Brain Metastases. J Clin Oncol. 2019; 37:1081–89.  
https://doi.org/10.1200/jco.18.01511. [PubMed]
79. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga 
J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu 
MW, Olsen S et al. Trastuzumab emtansine for HER2-
positive advanced breast cancer. N Engl J Med. 2012; 
367:1783–91. https://doi.org/10.1056/NEJMoa1209124. 
[PubMed]
Oncotarget6752www.oncotarget.com
80. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu 
M, Miles D, Samant M, Welslau M, Dieras V. Trastuzumab 
emtansine (T-DM1) versus lapatinib plus capecitabine 
in patients with HER2-positive metastatic breast cancer 
and central nervous system metastases: a retrospective, 
exploratory analysis in EMILIA. Ann Oncol. 2015; 26:113–
9. https://doi.org/10.1093/annonc/mdu486. [PubMed]
81. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen 
E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath 
Z, Galid A, Oehler L, Zielinski CC, Gnant M et al. 
Activity of T-DM1 in Her2-positive breast cancer brain 
metastases. Clin Exp Metastasis. 2015; 32:729–37. 
https://doi.org/10.1007/s10585-015-9740-3. [PubMed]
82. Berghoff AS, Preusser M. The inflammatory 
microenvironment in brain metastases: potential 
treatment target?Chin Clin Oncol. 2015; 4:21. 
https://doi.org/10.3978/j.issn.2304-3865.2015.06.03. [PubMed]
83. O'Kane GM, Leighl NB. Systemic Therapy of Lung Cancer 
CNS Metastases Using Molecularly Targeted Agents and 
Immune Checkpoint Inhibitors. CNS Drugs. 2018; 32:527–
42. https://doi.org/10.1007/s40263-018-0526-4. [PubMed]
84. Weber J. Review: anti-CTLA-4 antibody ipilimumab: 
case studies of clinical response and immune-
related adverse events. Oncologist. 2007; 12:864–72. 
https://doi.org/10.1634/theoncologist.12-7-864. [PubMed]
85. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey 
CL, Lao CD, Schadendorf D, Dummer R, Smylie M, 
Rutkowski P, Ferrucci PF, Hill A, Wagstaff J et al. 
Combined Nivolumab and Ipilimumab or Monotherapy 
in Untreated Melanoma. N Engl J Med. 2015; 373:23–34. 
https://doi.org/10.1056/NEJMoa1504030. [PubMed]
86. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann 
K, McDermott D, Linette GP, Meyer N, Giguere JK, 
Agarwala SS, Shaheen M, Ernstoff MS, Minor D et 
al. Nivolumab and ipilimumab versus ipilimumab in 
untreated melanoma. N Engl J Med. 2015; 372:2006–17. 
https://doi.org/10.1056/NEJMoa1414428. [PubMed]
87. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman 
JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, 
Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J 
et al. Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med. 2010; 363:711–23. 
https://doi.org/10.1056/NEJMoa1003466. [PubMed]
88. Margolin K, Ernstoff MS, Hamid O, Lawrence D, 
McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol 
M, Logan TF, Richards J, Michener T, Balogh A et al. 
Ipilimumab in patients with melanoma and brain metastases: 
an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 
459–65. https://doi.org/10.1016/S1470-2045(12)70090-6. 
[PubMed]
89. Di Giacomo AM, Ascierto PA, Pilla L, Santinami 
M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini 
L, Simeone E, Nicoletti SVL, Fonsatti E, Annesi D, 
Queirolo P et al. Ipilimumab and fotemustine in patients 
with advanced melanoma (NIBIT-M1): an open-label, 
single-arm phase 2 trial. Lancet Oncol. 2012; 13:879–86. 
https://doi.org/10.1016/S1470-2045(12)70324-8. [PubMed]
90. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, 
Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, 
Larkin J, Lorigan P, Neyns B et al. Pembrolizumab 
versus ipilimumab for advanced melanoma: final overall 
survival results of a multicentre, randomised, open-label 
phase 3 study (KEYNOTE-006). Lancet. 2017; 390: 
1853–62. https://doi.org/10.1016/S0140-6736(17)31601-X. 
[PubMed]
91. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst 
RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu 
L, Yu J, Hegde U, Speaker S et al. Pembrolizumab for 
patients with melanoma or non-small-cell lung cancer 
and untreated brain metastases: early analysis of a non-
randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 
17:976–83. https://doi.org/10.1016/S1470-2045(16)30053-5. 
[PubMed]
92. Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol 
M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, 
Perrotti E, Anderson G, Ralabate A et al. Long-Term 
Survival of Patients With Melanoma With Active Brain 
Metastases Treated With Pembrolizumab on a Phase 
II Trial. Journal of Clinical Oncology. 2019; 37:52. 
https://doi.org/10.1200/Jco.18.00204. [PubMed]
93. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, 
Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow 
MA, Atkins MB, Ernstoff MS, Reardon DA et al. 
Combined Nivolumab and Ipilimumab in Melanoma 
Metastatic to the Brain. N Engl J Med. 2018; 379:722–30. 
https://doi.org/10.1056/NEJMoa1805453. [PubMed]
94. Long GV, Atkinson V, Lo S, Sandhu S, Guminski 
AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, 
Scolyer RA, Menzies AM, McArthur GA. Combination 
nivolumab and ipilimumab or nivolumab alone in 
melanoma brain metastases: a multicentre randomised 
phase 2 study. Lancet Oncol. 2018; 19:672–81. 
https://doi.org/10.1016/S1470-2045(18)30139-6.
95. Teglasi V, Reiniger L, Fabian K, Pipek O, Csala I, 
Bago AG, Varallyai P, Vizkeleti L, Rojko L, Timar 
J, Dome B, Szallasi Z, Swanton C et al. Evaluating 
the significance of density, localization, and PD-1/
PD-L1 immunopositivity of mononuclear cells in the 
clinical course of lung adenocarcinoma patients with 
brain metastasis. Neuro Oncol. 2017; 19:1058–67. 
https://doi.org/10.1093/neuonc/now309. [PubMed]
96. Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, 
Kiyose M, Blasel S, Beschorner R, Senft C, Bender 
B, Ronellenfitsch MW, Wikman H, Glatzel M et al. 
Distribution and prognostic relevance of tumor-infiltrating 
lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints 
in human brain metastases. Oncotarget. 2015; 6:40836–49. 
https://doi.org/10.18632/oncotarget.5696. [PubMed]
97. Berghoff AS, Ricken G, Widhalm G, Rajky O, 
Dieckmann K, Birner P, Bartsch R, Holler C, Preusser 
Oncotarget6753www.oncotarget.com
M. Tumour-infiltrating lymphocytes and expression 
of programmed death ligand 1 (PD-L1) in melanoma 
brain metastases. Histopathology. 2015; 66:289–99. 
https://doi.org/10.1111/his.12537. [PubMed]
98. Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta 
P, Barker C, Midha A, Walker J. PD-L1 expression 
in advanced NSCLC: Insights into risk stratification 
and treatment selection from a systematic 
literature review. Lung Cancer. 2017; 112:200–15. 
https://doi.org/10.1016/j.lungcan.2017.08.005. [PubMed]
99. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive 
biomarkers in PD-1/PD-L1 checkpoint blockade 
immunotherapy. Cancer Treat Rev. 2015; 41:868–76. 
https://doi.org/10.1016/j.ctrv.2015.11.001. [PubMed]
100. Shukuya T, Carbone DP. Predictive Markers for 
the Efficacy of Anti-PD-1/PD-L1 Antibodies in 
Lung Cancer. J Thorac Oncol. 2016; 11:976–88. 
https://doi.org/10.1016/j.jtho.2016.02.015. [PubMed]
101. Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, Xu J, 
Zhao C, Liu R, Chu Y. The IFN-gamma/PD-L1 axis 
between T cells and tumor microenvironment: hints for 
glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 
2018; 15:290. https://doi.org/10.1186/s12974-018-1330-2. 
[PubMed]
102. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, 
Gordon MS, Sosman JA, McDermott DF, Powderly JD, 
Gettinger SN, Kohrt HE, Horn L, Lawrence DP et al. 
Predictive correlates of response to the anti-PD-L1 antibody 
MPDL3280A in cancer patients. Nature. 2014; 515:563–7. 
https://doi.org/10.1038/nature14011. [PubMed]
103. Gibney GT, Weiner LM, Atkins MB. Predictive 
biomarkers for checkpoint inhibitor-based 
immunotherapy. Lancet Oncol. 2016; 17:e542–e51. 
https://doi.org/10.1016/S1470-2045(16)30406-5. [PubMed]
104. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky 
JM, Desrichard A, Walsh LA, Postow MA, Wong P, 
Ho TS, Hollmann TJ, Bruggeman C, Kannan K et al. 
Genetic basis for clinical response to CTLA-4 blockade 
in melanoma. N Engl J Med. 2014; 371:2189–99. 
https://doi.org/10.1056/NEJMoa1406498. [PubMed]
105. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, 
Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, 
Miller ML, Rekhtman N, Moreira AL et al. Mutational 
landscape determines sensitivity to PD-1 blockade in 
non-small cell lung cancer. Science. 2015; 348:124–8. 
https://doi.org/10.1126/science.aaa1348. [PubMed]
106. Boussiotis VA. Somatic mutations and 
immunotherapy outcome with CTLA-4 blockade 
in melanoma. N Engl J Med. 2014; 371:2230–2. 
https://doi.org/10.1056/NEJMe1413061. [PubMed]
107. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada 
SA, Stenzinger A, Peters S. Development of tumor 
mutation burden as an immunotherapy biomarker: utility 
for the oncology clinic. Ann Oncol. 2019; 30:44–56. 
https://doi.org/10.1093/annonc/mdy495. [PubMed]
108. Allegretti M, Fabi A, Buglioni S, Martayan A, Conti 
L, Pescarmona E, Ciliberto G, Giacomini P. Tearing 
down the walls: FDA approves next generation 
sequencing (NGS) assays for actionable cancer genomic 
aberrations. J Exp Clin Cancer Res. 2018; 37:47. 
https://doi.org/10.1186/s13046-018-0702-x. [PubMed]
109. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, 
Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, 
Sanchez V, Sanders ME, Cook RS et al. RAS/MAPK 
Activation Is Associated with Reduced Tumor-Infiltrating 
Lymphocytes in Triple-Negative Breast Cancer: Therapeutic 
Cooperation Between MEK and PD-1/PD-L1 Immune 
Checkpoint Inhibitors. Clin Cancer Res. 2016; 22:1499–509. 
https://doi.org/10.1158/1078-0432.CCR-15-1125. [PubMed]
110. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert 
L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, 
Comin-Anduix B, Ribas A. Improved antitumor activity 
of immunotherapy with BRAF and MEK inhibitors 
in BRAF(V600E) melanoma. Sci Transl Med. 2015; 
7:279ra41. https://doi.org/10.1126/scitranslmed.aaa4691. 
[PubMed]
111. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu 
LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, 
Long GV, Scolyer RA. PD-L1 Expression and Tumor-
Infiltrating Lymphocytes Define Different Subsets of MAPK 
Inhibitor-Treated Melanoma Patients. Clin Cancer Res. 2015; 
21:3140–8. https://doi.org/10.1158/1078-0432.CCR-14-2023. 
[PubMed]
112. Okada H, Weller M, Huang R, Finocchiaro G, 
Gilbert MR, Wick W, Ellingson BM, Hashimoto 
N, Pollack IF, Brandes AA, Franceschi E, Herold-
Mende C, Nayak L et al. Immunotherapy response 
assessment in neuro-oncology: a report of the RANO 
working group. Lancet Oncol. 2015; 16:e534–e42. 
https://doi.org/10.1016/S1470-2045(15)00088-1. [PubMed]
